Evidence linking Taxotere and hair loss has been mounting for years. Sanofi-Aventis, the makers of Taxotere, sponsored a study called GEICAM 9805 to evaluate Taxotere in combination with other chemotherapy drugs for metastatic breast cancer. By 2005, the researchers found that 9.2% of patients (49 women) experienced persistent hair loss during the 10-year follow-up period.
Sanofi-Aventis is now accused of failing to warn women about the risk of permanent hair loss until December 2015, when the FDA updated the label.
Before the update, the label on Taxotere reassured patients that “hair generally grows back” after completing treatment. However, the drug-maker’s own studies estimated that 9% of patients experienced persistent or permanent hair loss.
If you or a loved one underwent chemotherapy for breast cancer and experienced:
You may be entitled to significant compensation from the manufacturer.
There are time deadlines to file a claim so don’t wait – act now.
Free Taxotere Legal Consultation
Thank you for submitting your information.